Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers-Reference-Cited by-同舟云学术

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

Published:2015-07-01 Issue:1 Volume:15 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Lane Denis,Matte Isabelle,Garde-Granger Perrine,Laplante Claude,Carignan Alex,Rancourt Claudine,Piché Alain

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/s12885-015-1511-7/fulltext.html

Reference62 articles.

1. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin. 1999;49:297–320.

2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA Cancer J Clin. 2010;60:277–300.

3. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–28.

4. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19–24.

5. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient‐derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways;Molecular Oncology;2024-09-08

2. Mitochondrial activity related genes of mast cells identify poor prognosis and metastasis of ovarian cancer;Immunobiology;2024-09

3. CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer;Science Advances;2024-07-12

4. EM-transcriptomic signature predicts drug response in advanced stages of high-grade serous ovarian carcinoma based on ascites-derived primary cultures;Frontiers in Pharmacology;2024-03-06

5. Limitations and potential of immunotherapy in ovarian cancer;Frontiers in Immunology;2024-01-09